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A B S T R A C T
Crohn's disease is a debilitating and incurable chronic inflammatory bowel disease, affecting millions of individuals worldwide, with an increasing frequency. Surgery
must be applicable in half of the cases often with a disabling course, and pharmacological treatments may have adverse complications. We generated three isogenic
clones of iPSCs from peripheral blood mononuclear cells (PBMCs) of a patient with Crohn's Disease under pharmacological treatment without adverse effects. Sendai
virus based vector was used and the iPSCs were characterized for genetic uniqueness, genomic integrity, pluripotency, and differentiation ability. These iPSCs will be
a powerful tool to develop tailored therapies.
Resource utility
Crohn's disease is an incurable chronic inflammatory bowel dis-
order, affecting millions of individuals. Surgery and pharmacological
treatments are the therapeutic options, but many adverse complica-
tions, such as pancreatitis frequently occur. The iPSCs can be a useful
tool to understand the disease and the pharmacological susceptibility
for developing new tailored therapies.
Resource details
Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD)
affecting more than 2.5 million individuals with an increasing in-
cidence (Molodecky et al., 2012). CD is debilitating and incurable, and
is characterized by intestinal ulceration and inflammation, commonly
affecting the distal small intestine. Surgery is an option in half of the
patients, but post-operative complications are possible; many pharma-
ceutical treatments are available, but they have been shown effective
only in 50% of the patients and can cause secondary deleterious effects,
such as pancreatitis (Boyapati et al., 2015; Fousekisa et al., 2019). The
iPSCs are definitively a flexible tool to generate tissue specific cells, for
amplifying knowledge, to better understand the disease and discover
susceptibility markers to complications and test more effective and safe
pharmaceutical treatments.
We generated iPSCs from PBMCs of a 17 years old male suffering of
CD, treated for many years with immunosuppressants. In particular, at
the moment of sample collection (6/6/2017), the patient has been in
therapy with azathioprine for five years without significant adverse
effects. The patient was in therapy also with infliximab (62 weeks) and
salazopirine and the disease was inactive. After transduction using the
CytoTune-iPS 2.0 Sendai Reprogramming Kit, based on a non-trans-
missible and non-integrating Sendai virus (SeV) vector carrying the
Yamanaka's factors OCT4, SOX2, KLF4, and c-MYC, in a feeder-free
condition, we selected three independent sub-clones (UNIBSi005-A,
UNIBSi005-B and UNIBSi005-C) (Table 1) positive for the Tra-1-60
stemness marker, and displaying ESC-like morphology (Fig. 1A). We
established the genetic uniqueness and identity of the clones to the
parental cells with STR analysis (Table 2). Karyotyping was performed
three times (P6, P15, and P33) using standard QFQ-banding, showing
the cell line original 46, XY pattern (Supplemental Fig. 1).
Pluripotency was assessed by both immunofluorescence staining
and gene expression analysis. The stem cell markers Tra-1-60 and OCT4
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were expressed on the cell surface, and at nuclear level, respectively
(Fig. 1B).
The expression of endogenous NANOG, OCT4, SOX2, c-MYC, and
KLF4 genes was investigated by SYBR qPCR, comparing the three clones
(passage p21), the patient primary PBMCs, and a commercial certifi-
cated control iPSC line (CTL-hiPSC, Gibco® Episomal hiPSC Line,
Cat#A18945). All clones showed a relative expression comparable to
that of the certified cell line (Fig. 1C).
Viral particles clearance was assessed by endpoint RT-PCR not de-
tecting transgenes expression (Fig. 1D).
After differentiation of iPSCs to ectoderm, mesoderm and endoderm
layers, using the commercial StemMACS™ Trilineage Differentiation Kit
(Miltenyi), we tested specific markers (PAX6, SOX1, CXCR4, ACTA2,
GATA4, and SOX17) through TaqMan qPCR comparing undifferentiated
iPSCs to the derived differentiated cells (Fig. 1E). The clones were de-
finitively able to differentiate into cells committed to the three germ
layers.
Moreover, mycoplasma contamination was excluded analysing the
16S rRNA gene conserved among the genus Mycoplasma (Fig. 1F).
In conclusion, we generated three iPSC clones from a patient with
CD not displaying adverse reactions to pharmacological treatments
(characterization summarized in Table 2, reagents in Table 3). Three
independent and isogenic clones are available to perform studies to
better clarify the disease mechanisms and susceptibility markers.
Materials and methods
Reprogramming of peripheral blood mononuclear cells (PBMCs)
PBMCs from a CD patient were reprogrammed to iPSCs using the
CytoTune-iPS 2.0 Sendai Reprogramming Kit (Thermo-Fisher-
Scientific) following manufacturer's instructions. Briefly, they were
cultured 4 days in StemPro®-34 SFM Medium (Thermo-Fisher-
Scientific) with the addition of SCF, FLT-3 (100 ng/ml), IL-3, and IL-6
(20 ng/ml) (Gibco) cytokines, and then infected with the SeV-based
Vector; after 21 days, the Tra-1-60 positive colonies were seeded on
Matrigel-coated plates (Corning) in daily changed Nutristem hPSC XF
medium (Biological-Industries), manually picked every 5 days with a
split ratio of 1:3, and incubated at 37 °C-5%CO2.
iPSC karyotyping
Karyotype was performed at passages p6, p15, and p33.
Proliferating iPSCs were blocked by 10 μg/ml of colcemid for 3 h
(KaryoMax, Gibco Co. BRL), detached by trypsin–EDTA, and swollen by
exposure to hypotonic KCl (0.075M) solution for 7min at 37 °C. Glass
slides were prepared with three steps of fixation in methanol/glacial
acetic acid (3:1). QFQ-banding at 400–450 bands resolution according
to the International System for Human Cytogenetic Nomenclature
(ISCN2016) was analyzed. A minimum of 20 metaphases and 3 kar-
yotypes were analyzed.
In vitro germ layers differentiation
StemMACS™ Trilineage Differentiation Kit (MiltenyiBiotec) was
used to commit iPSCs (p27) into differentiated cells of the three germ
layers. After seven days, the cells were collected for RNA extraction and
qPCR of the three germ layers specific genes.
Gene expression analysis
Total RNA was achieved by NucleoSpin® RNA II kit (Macherey-
Nagel) following manufacturer instructions. A deep gDNA contamina-
tion cleaning was performed by a TURBO-DNase (Ambion), if required
by the subsequent analyses. RNAs were retro-transcribed by ImProm-
II™ Reverse Transcription System (Promega). Transgenes were ampli-
fied by endpoint-PCR using Taq Gold™ (LifeTechnologies), and a
PE9700 thermocycler as described in the CytoTune-iPS 2.0 Sendai
Reprogramming Kit.
Pluripotency was assessed by qPCR using iTaq™ Universal SYBR®
Green Supermix (Bio-Rad), while gene expression of the markers
characterizing the three germ layers was evaluated by TaqMan qPCR
using iQ MPLX powermix (Bio-Rad). Tests were performed on the
CFX96 C1000 Touch™ Real-Time PCR Detection System, and analyzed
with the CFX manager software v.3.1 (Bio-Rad). The relative quantifi-
cation of target genes was calculated by the 2^− ΔΔCt method, using
βACTIN as housekeeping gene.
Immunofluorescence
The expression of the pluripotency markers Tra-1-60 and OCT4 was
verified by immunofluorescence. Briefly, cells grown on glass slides
were fixed 15min and permeabilized with the Fix & Perm-Reagents
(SIC) at room temperature (RT). Blocking was assessed by iBind™ Buffer
(Invitrogen) by incubation for 45min at RT. The primary antibodies
were incubated for 3 h at RT in blocking buffer, and the secondary
antibodies for 1 h at RT. Hoechst33342 (Thermo-Fisher-Scientific) was
used to stain nuclei. Mounting was performed with Glycerol/Gelatin
(Sigma-Aldrich). Images were acquired by an inverted fluorescence
microscope (Olympus IX70) and analyzed by the Image-Pro Plus soft-
ware v7.0 (Media-Cybernetics).
Mycoplasma detection
A standard PCR was performed to amplify the 16SrRNA of the genus
Mycoplasma from the supernatant of confluent cell culture and positive
and negative controls.
STR analysis
DNAs from parental PBMCs and iPSCs clones were achieved by the
QIAamp DNA Blood Mini kit (QIAGEN), and amplified with AmpFlSTR®
Identifiler® Plus (LifeTechnologies) following instructions.
Table 1
Summary of lines.
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease
UNIBSi005-A C1 male 17 Caucasian na Crohn's disease
UNIBSi005-B C5
UNIBSi005-C C20
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Fig. 1. A. iPSC clones morphology B. Immunofluorescence staining with the stemness markers Tra1-60 (green) and Oct4 (red). Nuclei were stained with
Hoechst33342 (blu), and the three channels were merged. C. Pluripotency markers expression D. Transgenes expression and SeV clearance analyses E. Expression
analysis of three germ layers markers F. Mycoplasma detection.
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Table 2
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal Fig. 1 panel A
Phenotype Qualitative analysis
Immunofluorescence
Positive for: OCT4, and Tra-1-60 Fig. 1 panel B
Quantitative analysis
Sybr Green RT-qPCR
Positive for: NANOG, OCT4, SOX2, c-MYC, KLF4 Fig. 1 panel C
Genotype Karyotype (Q-banding) 46,XY
Resolution: 400–450 bands
Supplemental Fig. 1
Identity STR analysis 16 distinct loci: all matched to parental cell line Available with the authors
Mutation analysis (If
Applicable)
Sequencing N/A N/A
Southern Blot OR WGS N/A N/A
Microbiology and virology Endpoint PCR for Mycoplasma 16S
rRNA
Negative Fig. 1 panel F
Differentiation potential In vitro Trilineage Differentiation Induction of selected genes expressed in the three germ layers (Ectoderm:
PAX6-SOX1; Endoderm: GATA4-SOX17; Mesoderm: ACTA2-CXCR4).
Fig. 1 panel E
Donor screening (Optional) HIV 1 + 2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info
(Optional)
Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
Table 3
Reagents details.
Antibodies used for immunocytochemistry/flow-cytometry
Antibody Dilution Company Cat # and RRID
Pluripotency markers Rabbit anti-OCT4 1:400 Thermo Fisher Scientific, Cat# A-13998. RRID: AB_2534182
Pluripotency markers Mouse anti-TRA-1-60 1:100 Thermo Fisher Scientific, Cat# 4110000. RRID: AB_2533494
Secondary antibodies Goat anti rabbit IgG (H+L) Alexa Fluor 568 1:300 Thermo Fisher Scientific, Cat# A-11011. RRID: AB_143157
Secondary antibodies Goat anti mouse IgG (H+L) Alexa Fluor 488 1:300 Thermo Fisher Scientific, Cat# A-11001. RRID: AB_2534069
Pluripotency Primers for RT-qPCR with SYBR Green chemistry
Target Forward/Reverse primer (5′-3′)
Pluripotency markers NANOG TGAACCTCAGCTACAAACAG/TGGTGGTAGGAAGAGTAAAG
Pluripotency markers OCT4 CCTCACTTCACTGCACTGTA/CAGGTTTTCTTTCCCTAGCT
Pluripotency markers SOX2 CCCAGCAGACTTCACATGT/CCTCCCATTTCCCTCGTTTT
Pluripotency markers C-MYC TGCCTCAAATTGGACTTTGG/GATTGAAATTCTGTGTAACTGC
Pluripotency markers KLF4 GATGAACTGACCAGGCACTA/GTGGGTCATATCCACTGTCT
House-keeping genes βACTIN CGCCGCCAGCTCACCATG/CACGATGGAGGGGAAGACGG
Transgenes Primers for endpoint PCR
Target Forward/Reverse primer (5′-3′)
Sendai virus detection KOS transgene ATGCACCGCTACGACGTGAGCGC/ACCTTGACAATCCTGATGTGG (528 bp)
Sendai virus detection SeV transgene GGATCACTAGGTGATATCGAGC/ACCAGACAAGAGTTTAAGAGATATGTATC (181 bp)
Sendai virus detection C-MYC transgene TAACTGACTAGCAGGCTTGTCG/TCCACATACAGTCCTGGATGATGATG (532 bp)
Sendai virus detection KLF4 transgene TTCCTGCATGCCAGAGGAGCCC/AATGTATCGAAGGTGCTCAA (410 bp)
Differentiation RT-qPCR assays with TaqMan chemistry
Target Probe
Ectoderm PAX6 Hs.PT.58.25914558
SOX1 Hs.PT.58.28041414.g
Mesoderm ACTA2 Hs.PT.56a.2542642
CXCR4 Hs00607978_s1
Endoderm GATA4 Hs.PT.58.259457
SOX17 Hs.PT.58.24876513
Housekeeping gene ACTB Hs.PT.39a.22214847
Mycoplasma detection
Target Forward/Reverse primer (5′-3′)
Genus Mycoplasma (GSO/MGSO) 16S rRNA GGGAGCAAACAGGATTAGATACCCT/TGCACCATCTGTCACTCTGTTAACCTC (268 bp)
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Key resources table
Unique stem cell lines
identifier
UNIBSi005-A
UNIBSi005-B
UNIBSi005-C
Alternative names of st-
em cell lines
iPSC-AG-Crohn-C1 (UNIBSi005-A)
iPSC-AG-Crohn-C5 (UNIBSi005-B)
iPSC-AG-Crohn-C20 (UNIBSi005-C)
Institution Department of Molecular and Translational Medicine,
University of Brescia, 25,123 Brescia, Italy
Institute for Maternal and Child Health IRCCS Burlo
Garofolo, 34,128 Trieste
Department of Life Sciences, University of Trieste, 34,127
Trieste
Department of Medical, Surgical and Health Sciences,
34,149 University of Trieste, Trieste
Contact information of
distributor
Gaetana Lanzi, g_lanzi@hotmail.com
Type of cell lines iPSC
Origin human
Additional origin info Age: 17
Sex: male
Ethnicity: Caucasian
Cell Source Blood
Clonality Clonal
Method of reprogram-
ming
CytoTune™-iPS 2.0 Sendai Reprogramming Kit (Thermo-
Fisher Scientific), expressing the four Yamanaka factors
OCT4, SOX2, KLF4, and c-MYC
Multiline rationale isogenic clones
Gene modification NO
Type of modification No modification
Associated disease Crohn's disease
Gene/locus NA
Method of modification NA
Name of transgene or r-
esistance
NA
Inducible/constitutive
system
NA
Date archived/stock da-
te
Feb-2018
Cell line repository/ba-
nk
https://hpscreg.eu/cell-line/UNIBSi005-A
https://hpscreg.eu/cell-line/UNIBSi005-B
https://hpscreg.eu/cell-line/UNIBSi005-C
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Supplementary data to this article can be found online at https://
doi.org/10.1016/j.scr.2019.101548.
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